Genomeditech(Shanghai) Co.LTD

EN

Insights

Press Release

Current position：News > Insights

Insights

IL-23:FDA approves Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease, expanding its use to the second major type of inflammatory bowel disease

Amgen’s IMDYLLTRA®▼ (tarlatamab) Granted a Conditional Marketing Authorisation for Third-Line Treatment of Extensive-Stage Small Cell Lung Cancer in the United Kingdom

GLP:Eden Unveils the World's First Compounded GLP-1 Rx Gummy

TL1A:Teva and Sanofi Announce Duvakitug (Anti-TL1A) Positive Phase 2b Results Demonstrating Best-in-Class Potential in Ulcerative Colitis and Crohn’s Disease

Merck Enters into Exclusive Global GLP-1：License Agreement with Hansoh Pharma for Investigational Oral GLP-1 Receptor Agonist

ROR1：Merck Sharp & Dohme Initiates Phase III Clinical Trial of ROR1 ADC

HER2：FDA signs off on Merus' first-in-class NRG1+ cancer drug Bizengri

GLP-1：Amgen’s MariTide Demonstrates 20% Weight Loss

IL-23：Protagonist Announces Positive Topline Results From Phase 3 ICONIC Studies of Icotrokinra

PD-1/VEGF BsAb : MSD Enters into Exclusive Global License for LM-299 from LaNova Medicines Ltd.

First Prev 3 4 5 6 7 Next Last

Total 7 Page

Jump

Current position：News > Insights

classify

Insights

IL-23:FDA approves Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease, expanding its use to the second major type of inflammatory bowel disease

Amgen’s IMDYLLTRA®▼ (tarlatamab) Granted a Conditional Marketing Authorisation for Third-Line Treatment of Extensive-Stage Small Cell Lung Cancer in the United Kingdom

GLP:Eden Unveils the World's First Compounded GLP-1 Rx Gummy

TL1A:Teva and Sanofi Announce Duvakitug (Anti-TL1A) Positive Phase 2b Results Demonstrating Best-in-Class Potential in Ulcerative Colitis and Crohn’s Disease

Merck Enters into Exclusive Global GLP-1：License Agreement with Hansoh Pharma for Investigational Oral GLP-1 Receptor Agonist

ROR1：Merck Sharp & Dohme Initiates Phase III Clinical Trial of ROR1 ADC

HER2：FDA signs off on Merus' first-in-class NRG1+ cancer drug Bizengri

GLP-1：Amgen’s MariTide Demonstrates 20% Weight Loss

IL-23：Protagonist Announces Positive Topline Results From Phase 3 ICONIC Studies of Icotrokinra

PD-1/VEGF BsAb : MSD Enters into Exclusive Global License for LM-299 from LaNova Medicines Ltd.

MORE

Insights

Press Release

Message consultation

                    
Toll-free hotline：400-627-9288
                    
Email address：mkt.genomeditech@gmail.com

Company address：5th Floor, Building 1, Lane 299, Kangwei Road, Pudong New District, Shanghai

Copyright © 2023 吉满生物科技（上海）有限公司 All rights reserved.

Message

Message consultation